tirzepatide surpass Efficacy and safety of monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial SURPASS-2: Tirzepatide bests semaglutide in
Pay in 4 interest-free payments of $6.54 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11


























